Athenex, Inc. (ATNX)
(Delayed Data from NSDQ)
$10.12 USD
+0.19 (1.91%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.09 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.12 USD
+0.19 (1.91%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.09 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -7.05% and 40.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Swedish Orphan Biovitrum (BIOVF) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 54.55% and 5.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Athenex (ATNX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Athenex (ATNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of 12.50% and 16.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Athenex (ATNX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of -76.92% and 6.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of -50% and 16.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 11.22% and 11.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Athenex (ATNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Athenex (ATNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.
Global Blood's (GBT) Earnings & Revenues Lag Estimates in Q3
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the third quarter of 2021 while its revenues miss estimates.
Horizon's (HZNP) Q3 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2021. The company lifts net sales guidance for 2021.
Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and 66.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports narrower-than-expected loss in the third quarter of 2021 while revenues surpass estimates.
Athenex (ATNX) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Athenex (ATNX) has been struggling lately, but the selling pressure may be coming to an end soon.
Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.
Athenex (ATNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin (BMRN) Beats on Q3 Earnings, Ups 2021 Guidance
by Zacks Equity Research
BioMarin's (BMRN) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company raises total revenue guidance and increases adjusted earnings guidance for 2021.
Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)
by Zacks Equity Research
The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal
by Zacks Equity Research
Galera's (GRTX) phase III ROMAN study on avasopasem for treating radiotherapy-induced severe oral mucositis in patients with head and neck cancer fails to meet its primary endpoint. Shares fall.
Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal
by Zacks Equity Research
Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.
Oyster Point's (OYST) Tyrvaya Gets FDA Nod for Dry Eye Disease
by Zacks Equity Research
The FDA approves Oyster Point's (OYST) Tyrvaya nasal spray for the treatment of the signs and symptoms of dry eye disease.
Bristol Myers (BMY) Gets Positive CHMP Opinion for Zeposia in UC
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends granting approval to Bristol Myers' (BMY) Zeposia for the treatment of adults with moderately to severely active ulcerative colitis.
Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug
by Zacks Equity Research
The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.